Pfizer said on Friday it may file for authorization of the Covid-19 vaccine it is developing with German partner BioNTech in late November, making it unlikely a vaccine will be available before U.S. elections as President Donald Trump has promised. Separately, a study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has “little or no effect” on death rates among hospitalized patients. CNBC's Meg Tirrell reports. For access to live and exclusive video from CNBC subscribe to CNBC PRO: Pfizer said on Friday it may file for authorization of the Covid-19 vaccine it is developing with German partner BioNTech in late November, making it unlikely a vaccine will be available before U.S. elections as President Donald Trump has promised.
The regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S. stock market.
The timeline now allows for a possible U.S. authorization of a coronavirus vaccine this year, a key step in controlling the Covid-19 pandemic, which has killed more than a million people and ravaged the global economy.
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:
Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:
#CNBC
#CNBCTV
0 Comments